Review
Open access
Aug 2026
Rethinking PDAC: from immunological silence to therapeutic opportunity
Pancreatic ductal adenocarcinoma (PDAC) ranks among the deadliest malignancies, with only 13% of patients surviving five years after diagnosis. This poor prognosis stems from late detection, treatment resistance, spatial and phenotypic heterogeneity, and a highly immunosuppressive tumor microenvironment. Unlike immunog...
S. K. Kali, Remya P. G. Ramesh, Aftab Alam et al.
· Frontiers in Immunology · 0 citations